KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2025 value amounting to $7.3 billion.

  • Jazz Pharmaceuticals' Total Non-Current Liabilities fell 8.59% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year decrease of 8.59%. This contributed to the annual value of $7.8 billion for FY2024, which is 3.71% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $7.3 billion for Q3 2025, which was up 2.02% from $7.1 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $8.9 billion for Q2 2021, and its period low was $2.9 billion during Q1 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $7.6 billion (2023), whereas its average is $7.5 billion.
  • In the last 5 years, Jazz Pharmaceuticals' Total Non-Current Liabilities soared by 220.77% in 2021 and then decreased by 12.06% in 2022.
  • Jazz Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $8.2 billion in 2021, then declined by 6.98% to $7.6 billion in 2022, then dropped by 1.19% to $7.6 billion in 2023, then climbed by 3.71% to $7.8 billion in 2024, then decreased by 8.59% to $7.3 billion in 2025.
  • Its last three reported values are $7.3 billion in Q3 2025, $7.1 billion for Q2 2025, and $7.3 billion during Q1 2025.